Topic Hub
25 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 25 of 25 clinical reviews.
A physician-level review of zoledronic acid (Reclast) use in post-bariatric surgery patients, covering fracture risk, dosing, calcium repletion, renal monitoring, and the HORIZON-PFT evidence base.
Read clinical reviewA clinician-level review of how zoledronic acid (Reclast) affects appetite and food cravings, including mechanism, trial data from HORIZON-PFT, and practical management guidance.
Read clinical reviewMD/PharmD-level review of zoledronic acid use in autoimmune disease: fracture data from HORIZON-PFT, immunomodulatory mechanisms, drug interactions with DMARDs and biologics, and dosing guidance for patients on corticosteroids.
Read clinical reviewA physician-reviewed, evidence-based guide to how zoledronic acid (Reclast) improves bone mineral density and reduces fracture risk, with primary-literature citations from HORIZON-PFT and other key trials.
Read clinical reviewA MD/PharmD-level review of the cancer risk signals associated with zoledronic acid (Reclast), covering osteonecrosis of the jaw, atypical femur fractures, renal toxicity, and emerging oncology data from HORIZON-PFT and post-marketing surveillance.
Read clinical reviewA clinician-level review of zoledronic acid's long-term cardiovascular effects, covering atrial fibrillation risk, mortality data from HORIZON-PFT, post-fracture cardiac outcomes, and practical prescribing guidance for osteoporosis patients.
Read clinical reviewDoes Reclast (zoledronic acid) affect cognition? An MD/PharmD-level review of HORIZON-PFT and subsequent evidence, covering proposed mechanisms, clinical risk data, and what patients should monitor.
Read clinical reviewA physician-level review of zoledronic acid (Reclast) graded by GRADE methodology, covering HORIZON-PFT and every major supporting trial, with fracture-reduction statistics, dosing guidance, and safety data.
Read clinical reviewA clinical deep-dive into zoledronic acid (Reclast) hair loss and skin reactions, covering incidence data, mechanisms, management, and when to escalate care.
Read clinical reviewDoes Reclast (zoledronic acid) affect liver function? MD/PharmD-level review of hepatic metabolism, ALT/AST changes, clinical trial data from HORIZON-PFT, and monitoring guidance for clinicians and patients.
Read clinical reviewA physician-reviewed deep dive into how zoledronic acid (Reclast) affects mental health, mood, cognition, and neuropsychiatric symptoms, with primary-literature citations and clinical guidance.
Read clinical reviewBoard-reviewed guide to zoledronic acid pharmacokinetics, bone metabolism effects, and emerging data on energy expenditure. Covers HORIZON-PFT, dosing, mechanism, and clinical protocol.
Read clinical reviewA physician-level review of zoledronic acid microdosing protocols, including HORIZON-PFT trial data, FDA-approved dosing, and whether fractionated or reduced doses have any clinical support.
Read clinical reviewA comprehensive, physician-reviewed guide to muscle preservation strategies when using Reclast (zoledronic acid) for osteoporosis, covering mechanisms, clinical trial data, exercise protocols, and nutritional co-management.
Read clinical reviewA clinician-level guide to diagnosing and managing inadequate response or plateau on zoledronic acid (Reclast) for osteoporosis, with primary-literature citations and a step-by-step decision framework.
Read clinical reviewA physician-level guide to the Reclast (zoledronic acid) pre-surgery hold window, covering timing, fracture risk, ONJ, atypical femur risk, and the evidence from HORIZON-PFT and current ASBMR guidelines.
Read clinical reviewWhat happens to bone turnover and fracture risk after stopping zoledronic acid (Reclast)? A physician-reviewed, primary-literature-based guide covering offset timing, rebound markers, and evidence-based transition protocols.
Read clinical reviewA clinical guide to timing, scheduling, and managing Reclast (zoledronic acid) infusions across seasons, covering vitamin D status, acute-phase reactions, flu season overlap, and post-infusion monitoring.
Read clinical reviewDoes Reclast (zoledronic acid) affect sexual function? A physician-reviewed, evidence-based review covering mechanisms, clinical trial data, hormonal interactions, and what patients and clinicians should monitor.
Read clinical reviewA clinical deep-dive into how zoledronic acid (Reclast) affects sleep architecture, including acute-phase reaction timing, neuroinflammatory mechanisms, and evidence-based management strategies for clinicians and patients.
Read clinical reviewMD/PharmD-level guide to scheduling Reclast (zoledronic acid) infusions around travel, timezone shifts, and logistical barriers. Covers timing windows, hydration protocols, pre-infusion labs, and what to do when an annual dose is delayed.
Read clinical reviewA physician-reviewed comparison of compounded zoledronic acid versus branded Reclast, covering clinical trial data, safety profiles, regulatory status, cost, and how to choose the right formulation for osteoporosis treatment.
Read clinical reviewA clinical deep-dive into how zoledronic acid affects kidney function, who is at risk, how to screen patients, and what protocols reduce nephrotoxicity based on HORIZON-PFT and current guidelines.
Read clinical reviewWhen and how to safely restart zoledronic acid (Reclast) after an acute illness, including nephrotoxicity risk, hydration protocols, and evidence from HORIZON-PFT.
Read clinical reviewA clinician-level, week-by-week guide to the first 30 days after a Reclast (zoledronic acid) infusion, covering acute-phase reactions, bone-marker changes, fracture protection timelines, and what requires a call to your provider.
Read clinical review